H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ardelyx today and set a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Caufield has given his Buy rating due to a combination of factors including the robust growth and strategic positioning of Ardelyx’s products. The company’s IBSRELA product has shown significant year-over-year growth, indicating strong commercial execution and demand among patients with IBS-C. This growth is supported by IBSRELA’s differentiation as a second-line treatment option, particularly for patients who experience side effects or inadequate control with other treatments like LINZESS.
Additionally, Caufield highlights the potential of Ardelyx’s pipeline, including the preclinical asset RDX 10531, which could further enhance their NHE3 inhibitor platform. The company’s strategic focus on expanding market penetration for both IBSRELA and XPHOZAH, despite challenges such as changes in Medicare coverage, reinforces the Buy rating. The continued commercial progress and targeted execution for XPHOZAH, evidenced by recent revenue growth, also contribute to the positive outlook for Ardelyx.
According to TipRanks, Caufield is a 5-star analyst with an average return of 16.9% and a 46.95% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Immunic, LENZ Therapeutics, and Mineralys Therapeutics, Inc..
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $14.00 price target.